Highlights From the Mass General Brigham 2025 Gene and Cell Therapy Institute Research Symposium
Trends and highlights from the 2025 Mass General Brigham Gene and Cell Therapy Research Symposium
IP Review: Tessera’s Therapy for Alpha-1 Antitrypsin Deficiency Disease - Engineering a $150M Gene Editor
What makes a $150M+ gene editor work? Taking a closer look at Tessera's approach to in vivo gene editing for treating alpha-1 antitrypsin deficiency.